Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Viva Biotech Holdings ( (HK:1873) ) just unveiled an update.
Viva Biotech Holdings announced its unaudited financial results for the first half of 2025, reporting a decrease in revenue to RMB 831.9 million compared to the previous year, but maintaining a stable gross profit. The company highlighted an improvement in its adjusted non-IFRS net profit margin, which rose to 22.1% from 17.1%, indicating a focus on operational efficiency and cost management. This financial performance reflects the company’s strategic efforts to enhance profitability despite a challenging market environment.
The most recent analyst rating on (HK:1873) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Viva Biotech Holdings stock, see the HK:1873 Stock Forecast page.
More about Viva Biotech Holdings
Viva Biotech Holdings is a company incorporated in the Cayman Islands, operating in the biotechnology sector. The company, along with its subsidiaries, focuses on providing services and products related to biotechnology, with a market emphasis on innovative solutions and financial performance.
Average Trading Volume: 10,323,027
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.28B
For a thorough assessment of 1873 stock, go to TipRanks’ Stock Analysis page.